Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03155932 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03155932 is a Phase 2 study that was terminated before completion, run by Arena Pharmaceuticals. The registered enrollment target is 2 participants.
The verdict
NCT03155932, a Phase 2 study, was terminated before completion, sponsored by Arena Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
Interventions
- DRUG APD334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03155932
The ClinicalTrials.gov registry entry for NCT03155932 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APD334 is the first listed.
NCT03155932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03155932 about?
NCT03155932 is a clinical study titled "Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis". The purpose of this open-label, pilot, proof of concept study is to evaluate the safety, tolerability, and efficacy of oral etrasimod (APD334) in participants with primary biliary cholangitis (PBC).
What is the current status of trial NCT03155932?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-12-29. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT03155932?
The interventions under investigation include: APD334 (DRUG).
Who is sponsoring clinical trial NCT03155932?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.